Takahara Akira, Sugiyama Atsushi, Satoh Yoshioki, Nakamura Yuji, Hashimoto Keitaro
Pharmaceutical Research Laboratories, Pharmaceuticals Company, Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki 210-8681, Japan.
J Pharmacol Sci. 2004 Oct;96(2):219-23. doi: 10.1254/jphs.scj04007x. Epub 2004 Oct 9.
Cardiovascular effects of cilnidipine, a dual L/N-type Ca2+ channel blocker, were evaluated in the chronic atrioventricular block dogs, of which systemic blood pressure and plasma catecholamine levels significantly increased in the pre-drug control. Administration of antihypertensive doses of cilnidipine (1 and 3 microg/kg, i.v.) significantly decreased the total peripheral vascular resistance, mean blood pressure, and atrial rate and increased the cardiac output. These results suggest that cilnidipine not only decreases the blood pressure, but also decreases the sinus automaticity in the in vivo hypertensive condition with increased adrenergic tones.
西尼地平是一种双L/N型钙通道阻滞剂,我们在慢性房室传导阻滞犬中评估了其心血管效应。在给药前的对照期,这些犬的全身血压和血浆儿茶酚胺水平显著升高。静脉注射抗高血压剂量的西尼地平(1和3微克/千克)可显著降低总外周血管阻力、平均血压和心房率,并增加心输出量。这些结果表明,在体内肾上腺素能张力增加的高血压状态下,西尼地平不仅能降低血压,还能降低窦房结自律性。